丙肝继续教育跃马巅峰__培训课件.ppt

派罗欣HCV Global Slide Kit Slide *. Peginterferon Alfa-2a [40KD] Plus RBV: SVR by HCV Genotype and Viral Load Additional analysis of results from the study by Fried and associates indicated that peginterferon alfa-2a [40KD] plus RBV in all patient subgroups was superior to standard IFN alfa-2b plus RBV regardless of HCV genotype or viral load. Absolute difference ranging from 8-16% and a relative difference ranging from 24-30%. Fried MW et al. N Engl J Med. 2002;347(13):975-82. Slide *. Peginterferon Alfa-2b [12KD] Plus RBV: SVR by HCV Genotype and Viral Load When evaluating SVRs by HCV genotype and viral load, investigators determined that peginterferon alfa-2b [12KD] plus RBV was only superior to standard IFN alfa-2b plus RBV in patients with HCV genotype 1 and low viral load.1,2 In other patient subgroups, there was no difference between treatment with peginterferon alfa-2b and standard combination therapy.1,2 Data for HCV genotype 2 or 3 patients according to low or high viral load are not publicly available. ? 1. PEG-Intron?. PDR ?. 56th ed. 2002. 2. Manns MP et al. Lancet. 2001;358:958-965. Full dose is defined as patients who receive at least 80% of the total PEGASYS? and ribavirin doses and receive therapy for at least 80% of the scheduled 48 weeks. Slide *. PEGASYS? plus 利巴韦林: clinical trial SVR rates mirrored in daily practice While overall response rates of 66% have been reported with PEGASYS? plus 利巴韦林 combination therapy have been achieved in phase III randomised-controlled trials, it is unclear if these results can be replicated in routine clinical practice. It is well known that patients selected for randomised-controlled trials represent a motivated, compliant subgroup with less comorbidities and associated problems. Results from clinics in three countries clearly show that the high SVR rates achieved with PEGASYS? plus 利巴韦林 in clinical trials are reflected in daily practice. 派罗欣HCV Global Slide Kit Reference: 1. Reddy K et al. The infl